Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey  by Garea-Rodríguez, Enrique et al.
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 i  g  h  l  i g  h  t  s
We  established  an  imaging  protocol  targeting  the  dopamine  transporter  in  common  marmoset  monkeys  by 123I-FP-CIT  SPECT.
High  resolution  imaging  was  achieved  with  an  upgraded  clinical  SPECT  camera  and  a 3T MRI  system.
Combination  of 123I-FP-CIT  SPECT  and  high  resolution  MRI  allows  for the  detection  of  small  dopaminergic  brain  structures.
The  presented  method  is a  suitable  imaging  tool  to be used  in  a marmoset  monkey  model  of  Parkinson’s  disease.
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a  b  s  t  r  a  c  t
Considerable  progress  has  been  made  in  small  animal  single  photon  emission  computed  tomogra-
phy  (SPECT)  imaging  in the  ﬁeld  of Parkinson’s  disease.  In  preclinical  research,  there  is an  increasing
demand  for  in  vivo imaging  techniques  to  apply  to animal  models.  Here,  we  report  the  ﬁrst  protocol  for
dopamine  transporter  (DAT)  SPECT  in common  marmosets  using  the  radioligand 123I-N--ﬂuoropropyl-
2-carbomethoxy-3-{4-iodophenyl}nortropane (123I-FP-CIT).  Serial  SPECT  images  were obtained  on
an upgraded  clinical  scanner  to determine  the  distribution  kinetics  of 123I-FP-CIT  in the  marmoset  brain.
After  intravenous  injection  of approximately  60 MBq  of the  radiotracer 123I-FP-CIT,  stable  and  speciﬁc
striatal  uptake  was  observed  for  at least  4 h. Analysis  of  plasma  samples  showed  rapid  disappearance
of  the radiotracer  from  blood  plasma  within  a few minutes  after  application,  with  activity  declining  toarkinson’s disease
-OHDA
4.1% of  the  administered  activity.  Structural  magnetic  resonance  imaging  (MRI)  at 400  m  resolution
provided  the  details  of the  underlying  anatomy.  In  a  marmoset  model  of  Parkinson’s  disease,  which  was
generated  by  unilateral  injections  of  6-hydroxydopamine  (6-OHDA)  into  the  nigro-striatal  projection
pathway,  complete  loss  of striatal  DAT  binding  in  combination  with  behavioral  deﬁcits  was  observed.
The  presented  study  demonstrates  that 123I-FP-CIT  SPECT  is  a suitable  tool  to investigate  DAT  integrity
in  preclinical  studies  on  common  marmosets.Abbreviations: 123I--CIT, 123I--carbomethoxy-3-(4-iodophenyl)tropane; 123I-IBZ
enzamide; 123I-FP-CIT, 123I-N--ﬂuoropropyl-2-carbomethoxy-3-{4-iodophenyl}no
orter;  DICOM, digital imaging and communications in medicine; FOV, ﬁeld-of-view; FLIR
f  gradient echoes; MRI, magnetic resonance imaging; NHP, non-human primate; NIFTI, 
ubset  expectation maximization; OWM,  Old World Monkey; PD, Parkinson’s disease; R
triatum.
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. Introduction
Parkinson’s disease (PD) is a disabling neurodegenera-
ive disease characterized by progressive neuronal cell loss
nd degeneration of nerve terminals of the nigro-striatal
opaminergic system (Dauer and Przedborski, 2003). Sin-
le photon emission computed tomography (SPECT) is a
aluable technique for clinical diagnosis and for studying
he pathogenesis of PD, e.g. by quantifying the decrease of
opamine transporters (DATs) in the striatum. As demon-
trated in many clinical trials, a reliable marker to image
ATs is the -emitting radioiodinated cocaine analog 123I-N--
uoropropyl-2-carbomethoxy-3-{4-iodophenyl}-nortropane
123I-FP-CIT) (Baldwin et al., 1995; Neumeyer et al., 1994; de la
uente-Fernández, 2012).
There is an increasing demand for in vivo imaging appli-
ations at the level of preclinical and translational research
sing non-human primates (NHPs), especially for long-term
tudies in animal models of Parkinson’s disease. Tradition-
lly, the most commonly used NHP species in PD research
re Old World monkeys (OWMs), such as baboons, rhesus
nd cynomolgus monkeys, (Baldwin et al., 1995; Booij et al.,
997; Prunier et al., 2003; Laruelle et al., 1993; Ma  et al.,
002).
Despite less frequent usage, the common marmoset monkey
Callithrix jacchus), a New World monkey species, provides a highly
ttractive model for preclinical research in PD. The common mar-
oset monkey is a small, day-active, NHP that is native to Brazil.
he animals are not threatened or endangered in the wild and
reed well in controlled laboratory conditions. They have a small
ody size of around 25 cm in length and a weight of 300–450 g
Mansﬁeld, 2003). Depending on the topic or substance under
nvestigation, utilization of marmoset monkeys can prove advan-
ageous over other species. This is the case, for example, when
harmacological agents for prospective use in humans cross react
ith marmoset – but not with macaque or baboon – binding
ites and/or when the generation of test substances is extremely
xpensive. Due to their much lower body mass relative to OWMs,
enerally less than 1/10th of a test substance is needed in the mar-
oset compared to OWMs  (Mansﬁeld, 2003; Orsi et al., 2011).
Since the development of pinhole and multi-pinhole colli-
ation (Beekman and van der Have, 2007; Schramm et al.,
003), considerable progress has been made in small animal
PECT imaging in the ﬁeld of Parkinson’s disease (Booij et al.,
002; Andringa et al., 2005; Lauwers et al., 2007; Alvarez-
ischer et al., 2007). Nevertheless, only Saji and colleagues
ave performed a PD-related brain SPECT study using common
armosets and two radiotracers the 123I-2-carbomethoxy-
-(4-iodophenyl)tropane (123I--CIT) and 123I-iodobenzamide
123I-IBZM) (Saji et al., 2003).
To the best of our knowledge, 123I-FP-CIT SPECT has not
een applied in marmosets. Yet, future preclinical models uti-
izing this technology have a high translational value since
23I-FP-CIT SPECT is well established in clinical diagnostics.
herefore, the aim of this study was to establish an imaging
rotocol for 123I-FP-CIT SPECT in common marmoset monkeys
nd to validate its use in the unilateral 6-OHDA model of
D.
able 1
verview of animals used in the present study.
Sex Age (year) Study protocol
Marmoset #1 M 5 Pharmacokinetic study: short
Marmoset #2 M 12 6-OHDA lesioning and behavi
study  at age of 12 years for hi
Marmoset #3 M 3 Control animal: high resolutiocience Methods 210 (2012) 195– 201
2. Materials and methods
2.1. Animals
Three adult (3, 5 and 12 years old) male common mar-
moset monkeys (Callithrix jacchus) (350–450 g) were used in this
study (Table 1). The animals were obtained from the breed-
ing colony at the German Primate Center (Göttingen, Germany)
and pair-housed in a temperature- (25 ± 1 ◦C) and humidity-
controlled (65 ± 5%) facility under a 12-h day/night cycle. Each cage
(80 cm ×150 cm × 66 cm,  Ebeco GmbH, Castrop-Rauxel, Germany)
was furnished with wooden branches and shelves and contained
a wooden sleeping box (24 cm ×21 cm × 18 cm). The animals were
fed ad libitum with a pelleted marmoset diet (ssniff Spezialdiäten,
Soest, Germany). In addition, 20 g mash per animal was  served in
the morning and they received 30 g clean-cut fruits or vegetables
mixed with noodles or rice in the afternoon. Water was  always
available. All animal experimentation was  carried out in accor-
dance with the European Council Directive of November 24 1986
(86/EC) including Position 6106/20 of the EU Council of May  26
2010, and was  approved by the Lower Saxony Federal State Ofﬁce
for Consumer Protection and Food Safety, Germany.
2.2. Pharmacokinetic study
The pharmacokinetic characterization was carried out on two
separate occasions in a single animal (marmoset #1) under gen-
eral anesthesia. Anesthesia was initiated by intramuscular injection
of diazepam (0.3 mg/kg, Diazepam®, Ratiopharm, Germany), alfax-
olon (10 mg/kg, Alfaxan®, Vetoquinol, UK) and glycopyrronium
bromide (0.01 mg  per animal, Robinul®; Riemser, Germany).
Subsequently, the animal was  intubated with a polyethylene endo-
tracheal tube (inner/outer diameter = 1.3/2.2 mm)  and kept under
inhalation anesthesia (0.4–1.0% isoﬂurane in 70:30 N2O O2). The
animal received an intravenous injection into the right saphenous
vein of approximately 60 MBq  of 123I-FP-CIT (Datscan®, Amersham
Buchler, Braunschweig, Germany). The radioactivity in the injection
syringe was measured immediately before and after injection with
an automated gamma  counter (PerkinElmer, Wizard 3, Waltham,
MA,  USA) to correct the injected dose for physical decay. Repeated
examinations of one animal yielded 138.1 (test) and 150.7 kBq/g
bodyweight (re-test) of 123I-FP-CIT.
Blood samples were obtained from the left saphenous vein 5, 15,
30, 60, 120, 180, 210 and 240 min  post injection, followed by plasma
centrifugation. Arterialisation of venous blood was  achieved by
hyperthermia in the animal’s lower extremities, induced by a
thermostat-controlled infrared radiator. Radioactivity values in
blood plasma were corrected for physical decay from t = 0. The
time course function xt = a1 + a2 × e(−k×t) was ﬁtted to the measured
plasma radioactivity values (mt) in order to calculate the initial
slope/rate constant of decay and the steady state radioactivity. The
radioactivity at the time of injection (xt = 0 = a1 + a2) was  calculated
from the injected dose and the volume of extracellular ﬂuid, which
was assumed to be 25% of the body mass (Swan et al., 1954). It was
estimated by the quotient of injected dose and distribution vol-
ume: D [Bq] ÷ (bodyweight [g] × 0.25 [ml/g]). Thus, it was implicitly
assumed that the tracer is initially distributed in the extracellular
 acquisition SPECT imaging and blood sampling
oral testing was  started at age of 3 years. Animal was included into presented
gh resolution SPECT/MRI
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uid and that there is a free exchange of 123I-FP-CIT between intra-
nd extra-vasal extracellular ﬂuid.
The method of minimizing the weighted sum of squares of
eviations
∑
0→t(mt − xt)2 was used. Weight was  set to 1/(mt)2.
urve ﬁtting was performed using Sigmaplot 11 (Systat Software,
ermany). In parallel with blood collection, serial SPECT images
ere taken to monitor 123I-FP-CIT brain uptake (see below).
.3. Brain SPECT
SPECT imaging was performed using a three-headed gamma
amera (Prism 3000XP, Picker International, Cleveland, OH, USA)
pgraded with a dedicated small-animal imaging module (HiSPECT,
civis, Göttingen, Germany). Each collimator head was  equipped
ith a pyramidal collimator and multi-pinhole aperture plate (6
inholes). The inner diameter of each pinhole was  2.5 mm,  which
ielded a tomographic resolution of 2.1 mm and an average on axis
ensitivity of 960 cps/MBq. The ﬁeld-of-view (FoV) was  143 cm3.
mages were acquired at 256 × 256 projection matrices with a pixel
ize of 1.78 mm over 10 gantry steps (30 projection angles) in a
tep-and-shoot mode. Up to 4 energy windows were acquired. An
cquisition time of 175 s per gantry step was chosen for time-
ctivity analysis (marmoset #1) resulting in a total scan time of
9.8 min. To obtain high quality images, as done for the 6-OHDA-
esioned (marmoset #2) and control animal (marmoset #3), a
onger acquisition time was chosen (300 s per angle and total scan
ime of 50.2 min). The photo peak energy was set to 159 keV with
 window of ±10%. Multi energy window scatter correction was
pplied. The anaesthetized animals were placed in a custom-made
older in prone position and the head was ﬁxed with ear bars.
tandard image acquisition (marmosets #2 and #3) was  initiated
fter reaching equilibrium state 2 h after injection of 50–60 MBq
23I-FP-CIT. In the pharmacokinetic study (marmoset #1), image
cquisition was started immediately after application of the tracer.
.4. SPECT reconstruction and evaluation
SPECT reconstruction was performed using a dedicated iterative
rdered subset expectation maximization (OSEM) algorithm con-
isting of three iterations and four subsets per iteration (HiSPECT®,
civis, Göttingen, Germany). The reconstructed voxel size was
.6 mm3. For quantiﬁcation, brain activity was determined with
iSPECT software. For time-course analysis (animal # 1), rectan-
ular shaped regions of interest (ROIs) of 74 mm3 volume were set
anually for the left (STl) and right striatum (STr) and cerebellum
CB) in reference to the corresponding MRI. 123I-FP-CIT brain uptake
as given as (Bq/l). Activities of left and right striatum were aver-
ged (ST = (STl + STr)/2). Speciﬁc binding in the ST was  calculated
y subtracting the mean activity in the CB from the mean activity
n the ST and dividing the result by the mean activity in the CB,
.e. (ST-CB)/CB. For the 6-OHDA-lesioned and control animal (ani-
als #2 and #3), ROIs of 370 mm3 volume were chosen in ST and
B with standard image acquisition. The binding ratio was  calcu-
ated separately for left and right striatum. A ROI with a volume
f 95 mm3 was chosen for the midbrain area (substantia nigra and
entral tegmental area). The binding ratio of the midbrain area was
alculated analogous to ST.
.5. Magnetic resonance imaging (MRI)
MRI  was performed on a 3T clinical MR  system (Magne-
om TIM TRIO, Siemens Healthcare, Erlangen, Germany) using an
-channel receive coil designed for the human wrist. Marmosets
ere scanned in supine position under general anesthesia with
iazepam (0.3 mg/kg i.m., Diazepam, Ratiopharm, Germany), alfax-
lon (10 mg/kg i.m, Alfaxan®, Vetoquinol, UK) and glycopyrroniumcience Methods 210 (2012) 195– 201 197
bromide (0.01 mg  per animal i.m., Robinul®; Riemser, Germany).
The total measurement time for structural MRI was about 10 min,
thus eliminating the need to intubate the animal.
Structural MRI  with T1-w(eighted) and T2-w(eighted) contrast
was performed at 0.4 mm  isotropic resolution with non-selective
excitation. The three-dimensional (3D) imaging volume covered
the head and upper chest with the read-out direction along the
body axis. The FoV in the right-left ventral-dorsal direction was
51.2 mm.
T1-w contrast was  achieved by magnetization-prepared rapid
acquisition of gradient echoes (MP-RAGE) using parameters rec-
ommended for humans (inversion time TI = 0.9 s, ﬂip angle  ˛ = 9◦,
bandwidth BW = 200 Hz/pixel, echo time TE = 4.06 ms,  repetition
time TR = 2.25 s,) (Jack et al., 2008), notwithstanding minor putative
differences in T1 (Bock et al., 2009). The matrix of 320 × 128 × 128
was acquired in 4:18 min.
T2-w 3D turbo spin-echo (TSE, not shown) with variable ﬂip
angles (2 averages with phase partial Fourier, slice turbo factor
of 2, yielding an echo train length of 75, effective TE = 278 ms  at
BW = 355 Hz/pixel; TR = 2.9 s). The matrix of 256 × 128 × 128 was
acquired in 5:26 min.
2.6. Post-processing of imaging data
The 2D digital imaging and communications in medicine
(DICOM) MRI  images in axial-to-coronal orientation were con-
verted to 3D neuroimaging informatics technology initiative (NIFTI)
volumes, changing from the radiological right-left convention to
left-right convention of the SPECT images. The T1-w volume was
aligned to a custom-made T1-w template of the marmoset head
and interpolated to 0.25 mm resolution in order to achieve consis-
tent angulation of the horizontal plane. This was deﬁned by the
intercommisural line, as featured in the stereotaxic atlas of the
National Institute of Neuroscience, Japan (Yuasa et al., 2010). This
T1-w volume then served as an individual anatomical reference to
align the T2-w and SPECT data, using the FMRIB software library
(FSL 4.1, Center for Functional Magnetic Resonance Imaging of the
Brain, University of Oxford, UK, www.fmrib.ox.ac.uk/fsl). For spa-
tial alignment, the FSL linear registration tool (FLIRT), was used to
determine the 3D rigid body transform (6 parameters) by a mutual
information criterion. A pixel mask of the brain was  deﬁned by the
characteristic T1-w and T2-w intensities of the brain, followed by
manual editing using FSLview.
2.7. Unilateral 6-hydroxydopamine lesion
The animal (marmoset #2) was  given unilateral 6-
hydroxydopamine (6-OHDA) injections into the nigrostriatal
bundle according to the protocol of Annett et al. (1992).  To protect
the noradrenergic and serotonergic pathways from the toxic
effects of 6-OHDA, the marmoset was pre-treated with the nora-
drenalin (NA) uptake blocker talsupram (Lundbeck, Copenhagen,
Denmark; 20 mg/kg) (Arnt et al., 1985) and the serotonin uptake
blocker citalopram (Lundbeck, 5 mg/kg) (Hyttel, 1982) in sterile
solution subcutaneously 30 min  prior to the injections of 6-OHDA.
Surgery was  carried out under Alfaxalon/Alfadolon anesthesia
(Saffan, Schering-Plough Ltd.; 18 mg/kg) and Diazepam (0.05 mg
per animal) anesthesia and aseptic conditions. 6-OHDA [8 mg/ml
free base weight 6-OHDA hydrobromide (Sigma–Aldrich, Stein-
heim, Germany) dissolved in 0.01% ascorbate-saline] was injected
stereotactically into four sites within the nigrostriatal bundle on
one side of the brain (coordinates: ﬁrst site: 2 l at AP+6.5; L+1.2,
V+6; second site: 2 l at AP+7, L+2.2, V+6.5; third site: 2 l at AP+7,
L+2.2, V+7.5; and fourth site: 3 l at AP+6.5; L+3.2, V+7.5; accord-
ing to Stephan et al. (1980).  The 6-OHDA was  freshly prepared
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insufﬁcient at concentrations below 30 MBq  (<80 kBq/g body-
weight, data not shown). No adverse effects of the tracer were
observed.98 E. Garea-Rodríguez et al. / Journal of N
nd stored on ice just before use. Each injection of 6-OHDA was
ade at a rate of 0.5 l/min using a 24-gauge injection needle,
hich was left in place for a further 4 min  after each injection
ad been made. Following surgery, the monkey was  given an
nalgesic and kept in a warm incubator until it was  well enough
o be returned to its home cage. Postoperatively, the animal was
reated with meloxicam (0.2 mg/kg i.m., Metacam®,Boehringer
ngelheim, Germany) for 3 days and enroﬂoxacin (5 mg/kg i.m.,
aytril®, Bayer, Germany) for 5 days. Before the lesioning, the
and preference of the animal was assessed using the staircase
est (see below) and the animal was injected with 6-OHDA on the
ontra-lateral side of the preferred hand in order to maximize the
ffect of motor impairments.
.8. Behavioral test: the staircase task
The staircase task is a behavioral test to assess skilled forelimb
eaching and was adapted to marmoset monkeys by Eslamboli et al.
2003). A single animal (marmoset #2) was tested in the staircase
ask. This test requires the animal to collect small baits arranged on
 series of ﬁve steps either ascending toward the midline (staircase
ill) or descending toward the midline (staircase valley).  The test
pparatus is made of clear Plexiglas ﬁxed to the front of the home
age during testing. Thus, the animal is tested in a familiar envi-
onment and handling is not required. The monkey is trained to
each through a vertical slot on the left or right side of the Plexiglas
pparatus in order to retrieve small gum arabic pieces (∼5 mm3), so
oth hands are needed for the successful completion of the task. The
onkey was presented with 2 trials for each test (staircase hill and
taircase valley).  The success rate of the coordinated hand move-
ents were scored as follows: grabbing and eating the reward was
cored with 1–5 points, depending on the distance of the stair from
he vertical slot. The reward on the nearest staircase was worth
 point and the most distant was worth 5 points. In many cases,
he animal needed several attempts until he could ﬁnally obtain
he gum arabic pieces. Thus, if the animal could remove and eat
he reward at his ﬁrst attempt, then the corresponding score was
oubled. The maximum possible scores were 28 and 30 for the stair-
ase hill and staircase valley test, respectively. The scores of two
rials were averaged. The monkey were trained pre-lesion until he
as familiar with the apparatus and could readily retrieve the gum
rabic pieces from all steps. During this period, it also became evi-
ent which was  the preferred hand for the individual animal, so
he subsequent lesion was made in the contra-lateral hemisphere.
he animal was trained for the task for 6 months before lesioning.
fter the lesion, he was tested twice a month for two years and then
nce a month for 3 years. Importantly, the animal was  not food- or
ater-deprived prior to the test.
ig. 1. Pharmacokinetics of 123I-FP-CIT brain uptake. Representative image of ani-
al  #1 (left) taken at an early time point (50 min  post i.v. injection of tracer) shows
igh  fraction of unspeciﬁc binding. Two hours post-injection, unbound tracer has
een  washed out and intense 123I-FP-CIT binding is visible in the striatum (1) and
he  lacrimal glands (2) (right). Acquisition time: 29.8 min.cience Methods 210 (2012) 195– 201
3. Results
3.1. Dose determination
The mean activity applied in the present study was 56.9 ± 6.3
MBq [I-123]-FP-CIT (corresponding to 130.7 ± 19.1 kBq/g body-
weight). In our experience, a suitable concentration ranges
between 50 and 70 MBq  (100–170 kBq/g bodyweight, data not
shown). Concentrations above 70 MBq  (170 kBq/g bodyweight)
were not tested. The uptake of 123I-FP-CIT in the brain wasFig. 2. (A) Time-activity curves for regional 123I-FP-CIT brain uptake. Repeated mea-
surements were performed on two separate occasions (1st scan: circles, 2nd scan:
squares) in a single animal (animal #1) with an acquisition time of 29.8 min  per
scan. (B) Striatal to cerebellar binding ratios increase with time. (C) Radioactivity vs.
time curves for parent plasma radioactivity.
E. Garea-Rodríguez et al. / Journal of Neuroscience Methods 210 (2012) 195– 201 199
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c triatal
r
3
t
i
t
h
5
i
a
o
w
r
w
i
a
s
3
t
F
w
mig. 3. 123I-FP-CIT SPECT images of the common marmoset superimposed on T1-w
ontrol  animal (animal #3) (upper row). Unilateral 6-OHDA lesioning of the nigro-s
ow,  lesion is indicated by arrows). Acquisition time of SPECT images: 50.2 min.
.2. Pharmacokinetic study
Serial SPECT images were obtained to describe the distribu-
ion kinetics of 123I-FP-CIT in the marmoset brain. Shortly after
.v. injection of 123I-FP-CIT, the whole brain was ﬂooded with the
racer. The unbound tracer washed out over time, revealing a
igh and stable uptake of 123I-FP-CIT in the striatum after about
0 min  (Figs. 1 and 2A). The calculated striatal to cerebellar bind-
ng ratios increased with time and reached highest values at 4 h
fter injection of the tracer (Fig. 2B). Considering the stable plateau
f striatal 123I-FP-CIT uptake, the optimum acquisition time-point
as determined to be between 2 and 4 h after application of the
adioligand.
Analysis of blood samples showed that 123I was  eliminated
ithin a few minutes following application. Thirty minutes after
njection, the plasma activity declined on average to 4.1% of the
dministered activity and remained stable until the end of the mea-
urement after 4 h (Fig. 2C)..3. DAT scans of control and 6-OHDA-lesioned animals
High uptake of 123I-FP-CIT was observed in both striata in
he control animal, perfectly matching with the corresponding
ig. 4. Sagittal view of the control animal (animal #3) of the co-aligned volumes of SPEC
ith  MRI  allows for detection of deep brain dopaminergic nuclei, such as the substantia ni
ucosa  (4) and the thyroid gland (5). Caudatoputamen (1). The high tracer uptake in the striatum matches with anatomical structures in the
 forebrain bundle leads to complete loss of striatal DAT activity (animal #2) (lower
anatomical structures as revealed by the overlay onto MRI  (Fig. 3).
The highest 123I-FP-CIT uptake was observed in the more ros-
tral parts of striatum, where the signals from caudate nucleus
and putamen (referred to as caudatoputamen) could not be sep-
arated without the anatomical information of the underlying MRI.
The DAT signal was  less intense in the caudal part of the stria-
tum. Calculated binding ratios revealed values of 2.94 for the left
and 2.70 for the right caudatoputamen (Fig. 5B). The high sensi-
tivity of SPECT in combination with the high resolution of MRI
even enabled the detection of small dopaminergic midbrain struc-
tures (Fig. 4). Quantiﬁcation of the signals in the substantia nigra
together with the ventral tegmental area yielded a binding ratio of
1.91.
The suitability of DAT imaging was also tested in the uni-
lateral 6-OHDA lesion model of PD as a proof of principle.
Injections of 6-OHDA into the nigro-striatal projection path-
way resulted in complete loss of striatal DAT binding (Fig. 3),
which was  accompanied by overt behavioral deﬁcits (Fig. 6).
Quantiﬁcation of 123I-FP-CIT uptake revealed binding ratios of
4.73 for the untreated contra lateral side and 0.09 for the
lesioned side (Fig. 5A). DAT scans were taken eight years after
lesion, proving long-lasting chronic effects of 6-OHDA in this
model.
T (color overlay) and MRI  (greyscale). High resolution 123I-FP-CIT SPECT co-aligned
gra (2). Outside of the brain, 123I-FP-CIT accumulates in the lacrimal gland (3), nasal
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Fig. 5. Striatal to cerebellar binding ratios of a unilaterally 6-OHDA-lesioned animal
(animal #2) (A) and a healthy control (animal #3) (B).
Fig. 6. Long-term behavioral assessment of a 6-OHDA-lesioned monkey (animal
#2). After lesioning, the animal failed to score in the staircase hill (A) and staircase
valley test (B) when using the affected left hand (ﬁlled circles). Motor impairment
remained chronic for at least 5 years.cience Methods 210 (2012) 195– 201
3.4. Behavioral analysis
Before surgery, the animal showed similar scores for the left
(26.72 ± 1.54) and right hand (26.06 ± 1.94) in the staircase hill task
(Fig. 6A). Following 6-OHDA lesioning, the animal’s left hand ﬁne
motor skills were severely impaired and the animal could not com-
plete the task with this hand (1st year score: 1.1 ± 1.64). In contrast,
when using the right unaffected hand, the average annual score
(1st year: 25.08 ± 3.54) was similar to the pre-lesion values. Fine
motor skill impairments of the left hand remained stable over a
time period of 5 years (2nd year: 0.13 ± 0.39, 3rd year: 0.11 ± 0.40,
4th year: 0.14 ± 0.45, 5th year: 0.23 ± 0.83). As expected, ﬁne motor
skills of the right hand were not affected by lesion and remained in
the control range over the years (average annual scores: 2nd year:
24.6 ± 2.73, 3rd year: 25.18 ± 4.79, 4th year: 25.73 ± 1.55, 5th year:
25.88 ± 2.32).
Pre-lesion scores were similar for the left (29.11 ± 1.45) and
right hand (27.0 ± 3.79) in the stair case valley task (Fig. 6B). After
surgery, a strong decrease in the average annual score was observed
for the left affected hand (1st year: 1.56 ± 2.94). The score remained
low over the following 3 years (2nd year: 0.03 ± 0.11, 3rd year:
0.0, 4th year: 1.91 ± 3.20), but slightly increased in the ﬁfth year
(5th year: 7.0 ± 5.47). In contrast, ﬁne motor skills of the right
hand remained unaffected throughout the entire experiment and
no change in the scores of this hand was observed (1st year:
25.32 ± 3.78, 2nd year: 24.63 ± 5.32, 3rd year: 27.18 ± 2.82, 4th
year: 26.73 ± 4.1, 5th year: 25.88 ± 3.83).
4. Discussion
The aim of this study was  to establish DAT imaging in the com-
mon  marmoset using 123I-FP-CIT SPECT. Here, we  used clinical
equipment specially adapted for high resolution scanning of mar-
moset monkeys.
Pharmacodynamic time course analysis showed high and sta-
ble striatal binding of 123I-FP-CIT for at least 4 h, indicating high
speciﬁcity of 123I-FP-CIT for DAT (Laruelle et al., 1993; Lundkvist
et al., 1995). Similar patterns of brain uptake were reported for
humans (Kuikka et al., 1995), Old World monkeys (Baldwin et al.,
1995; Lundkvist et al., 1995; Booij et al., 1997) and rodents (Booij
et al., 1997, 2002; Alvarez-Fischer et al., 2007), suggesting uni-
versal applicability of 123I-FP-CIT SPECT for DAT-related diseases.
The individual differences in binding ratio between the unaffected
contra lateral side of the 6-OHDA-lesioned animal and the con-
trol animal are within range of previously reported studies (Booij
et al., 2002; Andringa et al., 2005). KD binding experiments were
not performed in the present study. However, the speciﬁcity of
123I-FP-CIT for DAT and its suitability for PD diagnostics has been
proven in other studies (Seibyl et al., 1998; Booij et al., 1998; de la
Fuente-Fernández, 2012).
Measurements of 123I-FP-CIT activity in plasma of common mar-
mosets demonstrated that the elimination of the radioligand from
plasma share the same kinetics as in humans (Booij et al., 1998) and
is similar to the elimination kinetics of 11C--CIT-FP in cynomolgus
monkeys (Lundkvist et al., 1995). Lipophilic radioiodinated plasma
metabolites may  marginally interfere with SPECT quantiﬁcation
(Lundkvist et al., 1995; Bergström et al., 1996; Heinz et al., 1997).
Although the DAT scans did not feature sufﬁcient anatomical
detail to outline nuclear territories of the basal ganglia, the global
intensity pattern could be robustly aligned to high-resolution
structural MRI  scans. Thus, ROIs of single deep brain nuclei can
be deﬁned for speciﬁc analysis and monitoring of concomitant
volumetric changes. Our co-registration approach employed the
intercommisural line as stereotaxic reference to ensure compa-
rability between scans of the same animal as well as consistent
display of different individuals.
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Unilateral 6-OHDA injections into the nigro-striatal projection
athway led to complete loss of striatal DAT binding. This result
orresponds well to the behavioral impairments of ﬁne motor
kills which were clearly detectable over 5 years following lesion-
ng. Thus, the in vivo imaging and behavioral data exemplify the
hronicity of the lesion protocol. These results are supported by
ther behavioral and histological data obtained after 6-OHDA appli-
ations in marmosets (Annett et al., 1994; Eslamboli et al., 2003).
23I-FP-CIT SPECT was evaluated in various rodent models of PD
Lauwers et al., 2007; Andringa et al., 2005; Alvarez-Fischer et al.,
007; Booij et al., 2002). Until now, the only study that applied
AT SPECT to common marmosets was a reported by Saji and
olleagues, who evaluated 123I--CIT in the 1-methyl-4-phenyl-
,2,3,6-tetrahydropyridine (MPTP) model of PD (Saji et al., 2003).
In future studies, 123I-FP-CIT SPECT may  be an addition or alter-
ative to behavioral assessments in non-human primate models
f PD. Long-term monitoring in vivo by SPECT imaging would be
specially advantageous in viral vector-mediated alpha-synuclein
xpressing approaches, in which parkinsonian symptoms slowly
evelop (Kirik et al., 2003; Eslamboli et al., 2007). Especially, future
herapeutic approaches in marmoset models of PD will beneﬁt from
ongitudinal studies of individual disease courses, thus increasing
he relevance and impact for translational research.
. Conclusion
The presented work provides the ﬁrst 123I-FP-CIT SPECT proto-
ol for application in common marmoset monkeys. The upgraded
uman scanner used in the present study, allows for future long-
erm and translational approaches. High resolution 123I-FP-CIT
PECT and MR  imaging appears to be a suitable combination for
nvestigating DAT integrity and individual morphology in mar-
oset models of PD.
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